论文部分内容阅读
目的分析环磷酰胺联合VAD方案治疗多发性骨髓瘤临床疗效。方法 60例多发性骨髓瘤患者,随机分为观察组和对照组,每组30例。对照组患者采用VAD方案治疗,观察组患者采用环磷酰胺联合VAD方案治疗,比较两组患者治疗后的总有效率、尿液轻链含量、Karnofsky功能状态评分(KPS评分)和血尿素氮(BUN)水平。结果观察组患者治疗后尿液轻链含量(11.17±4.35)mg、KPS评分(3.37±0.25)分、BUN(16.41±4.21)mmol/L,均优于对照组患者的(16.38±5.15)mg、(4.17±1.26)分、(23.15±5.74)mmol/L,差异有统计学意义(P<0.05)。观察组患者治疗后总有效率为93.33%,高于对照组患者的53.33%,差异有统计学意义(P<0.05)。结论环磷酰胺联合VAD方案治疗多发性骨髓瘤具有良好的临床疗效。
Objective To analyze the clinical efficacy of cyclophosphamide combined with VAD in the treatment of multiple myeloma. Methods Sixty patients with multiple myeloma were randomly divided into observation group and control group, 30 cases in each group. The patients in the control group were treated with VAD regimen. The patients in the observation group were treated with cyclophosphamide and VAD regimen. The total effective rate, urinary light chain, Karnofsky functional status score (KPS) and blood urea nitrogen BUN) level. Results The urine light chain (11.17 ± 4.35) mg, KPS score (3.37 ± 0.25) and BUN (16.41 ± 4.21) mmol / L in the observation group were better than those in the control group (16.38 ± 5.15) mg , (4.17 ± 1.26) points, (23.15 ± 5.74) mmol / L respectively, the difference was statistically significant (P <0.05). The total effective rate of the observation group was 93.33% after treatment, which was higher than that of the control group (53.33%), the difference was statistically significant (P <0.05). Conclusion cyclophosphamide combined with VAD regimen for treatment of multiple myeloma has good clinical efficacy.